Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Last trade$7.11
Day change-$0.01 (-0.14%)
Day range$7.00 – $7.50
Volume354,421
Market cap$560M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$560.38M
Price / earnings
—
Price / book
72.01×
Price / sales
17.96×
EV / sales
18.21×
EV / EBITDA
-9.38×
Profitability
Earnings per share
-$0.74
Return on assets
-54.17%
Return on equity
-749.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
4.58×
Current ratio
7.25×
Quick ratio
7.24×
Cash ratio
1.95×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$64.18M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OBIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$91K
$88K
$110K
$30.92M
$861K
$836K
$868K
$253K
Cost of revenue
$28K
$25K
$32K
$51K
$49K
$46K
$44K
$58K
Gross profit
$63K
$63K
$78K
$30.87M
$812K
$790K
$824K
$195K
Selling, general and administrative
$5.63M
$5.83M
$6.37M
$7.29M
$7.1M
$6.26M
$6.26M
$5.9M
Research and development
$17.73M
$16.59M
$15.78M
$16.82M
$14.03M
$13.85M
$13.48M
$10.97M
Total operating expenses
$23.36M
$22.42M
$22.15M
$24.11M
$21.13M
$20.12M
$19.75M
$16.87M
Operating income
-$23.3M
-$22.36M
-$22.08M
$6.75M
-$20.31M
-$19.33M
-$18.92M
-$16.68M
Interest expense
-$2.46M
-$1.77M
$0
$0
-$515K
-$36K
$0
$0
Income before taxes
-$18.75M
-$23.76M
-$20.69M
$6.25M
-$20.83M
-$19.36M
-$18.76M
-$16.16M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$18.75M
-$23.76M
-$20.69M
$6.25M
-$20.83M
-$19.36M
-$18.76M
-$16.16M
Net income attributable to common shareholders
-$19.62M
-$24.08M
-$20.66M
$5.99M
-$20.83M
-$19.36M
-$18.76M
-$16.16M
EBITDA
-$23.2M
-$22.26M
-$21.99M
$6.84M
-$20.23M
-$19.25M
-$18.84M
-$16.59M
Basic earnings per share
-$0.30
-$0.38
-$0.33
$0.10
-$0.40
-$0.50
-$0.49
-$0.42
Diluted earnings per share
-$0.30
-$0.38
-$0.33
$0.10
-$0.40
-$0.50
-$0.49
-$0.42
Recent news
Company coverage with links to the original publishers.
Orchestra BioMed Holdings (OBIO) has a mean analyst price target of $12.50, suggesting 72.4% upside potential from its current $7.25 price. The stock has gained 33% over the past four weeks and holds a Zacks Rank #2 (Buy) rating. Analysts have revised earnings estimates upward over the last 30 days, though the article cautions that price targets should not be the sole basis for investment decisions.
Orchestra BioMed (OBIO) announced the pricing of an underwritten public offering of 15 million shares at $5.00 per share, expected to raise $75 million in gross proceeds. The company plans to use the funds to advance its AVIM Therapy program and BACKBEAT clinical trial for hypertension treatment, as well as its Virtue SAB program for coronary in-stent restenosis, alongside other research and development initiatives.
Guardant Health reported a quarterly loss of $0.29 per share, matching consensus estimates and improving from a $0.39 loss a year ago. The company exceeded revenue expectations with $360.98 million, up from $265.2 million year-over-year. The stock has gained 65.1% since the beginning of the year, significantly outperforming the S&P 500's 12.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced its inclusion in the Russell 3000 Index and Russell 2000 Index following the 2026 Russell indexes reconstitution effective June 26, 2026. The biomedical company develops AVIM Therapy for hypertension in collaboration with Medtronic and Virtue SAB for atherosclerotic artery disease, both undergoing pivotal clinical trials.
Orchestra BioMed (OBIO) announced its participation in two major institutional investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference (March 3rd) and the Barclays 28th Annual Global Healthcare Conference (March 11th). Management will conduct fireside chats and one-on-one investor meetings at both events.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.